Protective Effect of Biochanin A on the Diabetes-Induced Renal Damage

Angiogenesis and oxidative stress contribute to the pathogenesis of diabetic nephropathy (DN). The isoflavone biochanin A (BCA) has reported anti-inflammatory and antioxidant properties; we evaluated whether BCA modulates inflammatory and angiogenic markers in renal tissue of streptozotocin-induced diabetic rats.

Thirty-six male Wistar rats (180-200 g) were randomized into six groups (n = 6): non-diabetic control (vehicle), diabetic control (STZ 55 mg/kg, i.p.), and two diabetic groups treated with BCA (10 or 15 mg/kg; Oral). Treatments were administered for 42 days. On day 42 animals were sacrificed and blood and renal tissues collected. Renal VEGF, TNF-α, IL-1β, IL-6, IL-18, NF-κB, TGF-β, RAGE, CTGF, and MDA were measured by ELISA. Renal tissues evaluate histopathologically for mesangial expansion, cellularity, and angiogenesis.

BCA treatment reduced fasting blood glucose in diabetic rats and significantly decreased renal VEGF, TNF-α, and IL-1β concentrations versus diabetic controls (p < 0.05). No clear dose-response was observed between 10 and 15 mg/kg; other markers showed non-significant trends toward improvement.

BCA reduced key angiogenic and proinflammatory markers in diabetic rat kidney, suggesting potential nephroprotective effects; further studies are needed to define mechanisms, optimal dosing, and long-term safety.